Liquid Dose Featured Articles

  1. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

  2. Why Spray Drying Is Gaining Attention 7/20/2026

    Facing patent cliffs, pharma companies can leverage spray drying to reformulate complex biologics, enabling non-invasive delivery, boosting patient convenience, and securing new patents.

  3. Rethinking Fill-Finish To Reduce API Loss In Early Development 6/15/2026

    Early-stage drug programs can preserve constrained API supplies by replacing large-scale manufacturing defaults with deliberate, right-sized fill-finish designs that minimize avoidable process waste.

  4. The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process 6/2/2026

    Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.

  5. Drug Substance To Fill-Finish Handoff: What Sponsors Need To Know 5/14/2026

    Effective drug substance handoff to fill-finish manufacturing depends on early collaboration, clear communication, and proactive planning to reduce risks, ensure quality, and maintain timelines.

  6. Gaining An Edge In GLP-1 Production 5/5/2026

    The shortage-driven production of GLP-1 drugs of the past few years is giving way to a long-term operation model characterized by digital enablement and supply chain resilience.

  7. How Generic Pharma Manufacturers Can Rebuild Margins Inside The Four Walls 5/4/2026

    The pricing dynamics for generic drugs turns formerly attractive products into high-volume, low-margin commodities. Lean and Six Sigma in four key areas can unlock efficiencies.

  8. Advancing TIDES Manufacturing Through Biocatalysis And Flow Technologies 4/17/2026

    Integrated biocatalysis and continuous processing are reshaping therapeutic manufacturing, enabling faster scale‑up, greater efficiency, and lower costs as peptides and oligonucleotides meet demands.

  9. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

  10. How Asia and Europe Are Reshaping Biologics Manufacturing 4/9/2026

    As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.